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(nomogram) for this prediction was to be developed.  Re-
sults: Serum concentrations of CA 125 and blood platelets in 
the group with residual tumor  1 1 cm were higher in com-
parison to the optimally cytoreduced group (p  ! 0.0001 and 
 ! 0.01, respectively). Serum albumin and hemoglobin levels 
were lower in the group with residual tumor (p  ! 0.0001 and 
 ! 0.05, respectively). The frequency of preoperative ascites 
was higher in the group with residual tumor (p  ! 0.0005). The 
prediction model, consisting of CA 125 and albumin, for re-
maining with residual tumor showed an area under the re-
ceiver operating characteristics curve of 0.79. A nomogram 
for probability of residual tumor  1 1 cm based on serum lev-
els of CA 125 and albumin was established.  Conclusion: 
Postoperative residual tumor despite maximal surgical ef-
fort can be predicted by preoperative CA 125 and serum al-
bumin levels. With a nomogram based on these two param-
eters, probability of postoperative residual tumor in each 
individual patient can be predicted. This proposed nomo-
gram may be valuable in daily routine practice for counsel-
ing and to select treatment modality. 
 Copyright © 2008 S. Karger AG, Basel 
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 Abstract 
 Objectives: Suboptimal debulking ( 1 1 cm residual tumor) 
results in poor survival rates for patients with an advanced 
stage of ovarian cancer. The purpose of this study was to de-
velop a prediction model, based on simple preoperative pa-
rameters, for patients with an advanced stage of ovarian 
cancer who are at risk of suboptimal cytoreduction despite 
maximal surgical effort.  Methods: Retrospective analysis of 
187 consecutive patients with a suspected clinical diagnosis 
of advanced-stage ovarian cancer undergoing upfront de-
bulking between January 1998 and December 2003. Preop-
erative parameters were Karnofsky performance status, as-
cites and serum concentrations of CA 125, hemoglobin, 
albumin, LDH and blood platelets. The main outcome pa-
rameter was residual tumor  1 1 cm. Univariate and multivar-
iate logistic regression was employed for testing possible 
prediction models. A clinically applicable graphic model 
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 Introduction 
 Ovarian cancer is the second most frequent gyneco-
logical cancer in developed countries. It is the fourth 
most common cause of cancer-related death in women 
worldwide, accounting for 5% of all cancer deaths in 
women  [1] . Efficient and cost-effective screening tools 
for ovarian cancer are currently unavailable  [2–5] . As a 
result of the insidious onset of ovarian cancer, at least 
two thirds of cases remain undetected before disease 
progression to an advanced stage  [6] . Common features 
of patients with advanced ovarian cancer are ascites, a 
decreased Karnofsky performance status (PS), thrombo-
cytosis, anemia, and elevated serum levels of cancer an-
tigen 125 (CA 125) and lactate dehydrogenase (LDH)  [7–
11] . In addition, transvaginal sonography or computed 
tomography may disclose enlarged ovaries  [12] , pelvic 
mass, ascites, lymphadenopathy, omental cake and peri-
toneal implants  [13] .
 In the Netherlands, the mean 5-year survival rate of 
women with epithelial ovarian cancer is 43%; however, 
up to 65% will eventually die from the disease  [14] . Cur-
rent standard management of ovarian cancer patients 
consists of surgical staging in early-stage disease [Inter-
national Federation of Gynecology and Obstetrics (FIGO) 
IA–IIA]. In case of an advanced stage of ovarian cancer 
(FIGO IIB–IV), staging is followed by upfront debulking 
in a maximal effort to achieve an optimal cytoreduction. 
Without exception, these patients are subsequently treat-
ed with chemotherapy  [15, 16] . However, in a subset of 
patients, this might not be the most effective approach 
since optimal cytoreduction may not be achieved in all 
patients by upfront surgical debulking  [17–21] .
 Prior to surgery, identification of patients with an ad-
vanced stage of epithelial ovarian carcinoma with a low 
chance of optimal cytoreduction is highly desirable. It 
has been suggested that in patients with preoperative CA 
125 levels  1 586 IU/l, residual tumor may be present post-
operatively despite upfront debulking  [8] . In addition, the 
parameters hemoglobin, blood platelets, albumin and 
LDH may help to identify patients who benefit most from 
primary surgical cytoreduction  [9, 22–24] .
 This observational longitudinal study was designed 
to identify preoperative predictors of patients with ovar-
ian cancer remaining with residual tumor despite maxi-
mal surgical effort. In addition, with the prediction 
model, a clinically simple tool for predicting the chance 
of residual tumor in each individual patient was to be 
designed.
 Patients and Methods 
 Selection of Patients and Study Design 
 By power analysis, based on previous studies and an incidence 
in ovarian carcinoma of 1,138 new cases/year in the Netherlands, 
a minimum of 151 patients was required to enter the study  [8, 25] . 
Subsequently, between January 1998 and December 2003, 187 
consecutive patients with ovarian cancer initially treated by sur-
gical staging and upfront surgical debulking were retrieved from 
the Ovarian Cancer Database. Eligibility criteria for inclusion in 
this study were clinical suspicion of advanced-stage ovarian can-
cer in patients undergoing surgical staging followed by an upfront 
surgical debulking procedure. The clinical staging of patients was 
based on clinical characteristics, radiodiagnostics (CT scans and/
or ultrasound) and laboratory results. All identified patients un-
derwent primary surgical staging and subsequent cytoreduction 
by qualified gynecologic oncologists in three affiliated special-
ized centers. Patients with a chance finding of ovarian carcinoma, 
previous neoadjuvant chemotherapy, benign ovarian disease and 
those with a coexistence or history of cancer were excluded from 
analysis. This study was approved by the Medical Ethical Com-
mittee and informed consent of the patients was obtained. In ad-
dition, this study was performed according to the standards out-
lined in the Declaration of Helsinki.
 Preoperative Workup and Surgical Procedure 
 In this analysis, age was defined as age at the time of diagnosis. 
Clinical condition of the patients was scored by means of the PS. 
Patients underwent physical examination and transvaginal so-
nography. CT scans were electively made at the discretion of the 
attending physician. Blood samples for the determination of se-
rum CA 125, blood platelet count, hemoglobin, albumin and LDH 
were taken prior to surgery. CA 125 levels were assessed by en-
zyme immunoassay (Roche E170) using a sandwich method with 
chemiluminescence (Roche Diagnostics, Almere, The Nether-
lands). The inter- and intra-assay coefficients of variation were 
2.8 and 0.2%, respectively. Serum levels of LDH and albumin were 
assessed by a Hitachi 917 system (Roche, Mannheim, Germany). 
The blood platelet count and hemoglobin were assessed using a 
Sysmex XE 2100 system (Sysmex, Kobe, Japan).
 Surgical staging and upfront debulking was performed by an 
abdominal midline incision with sampling of any ascitic fluid, 
total hysterectomy, bilateral salpingo-oophorectomy and omen-
tectomy. When indicated, tumor bulk was resected in addition to 
biopsy samples of suspicious areas. Blind samples of the paracol-
ic and parahepatic peritoneum were taken. Bowel and lymph 
node dissections were performed if required to achieve an opti-
mal cytoreduction, defined as residual tumor  ! 1 cm  [26] .
 Staging and Tumor Assessments 
 The stage of the disease was described as defined by FIGO  [27] . 
Tumors were histologically classified as serous, serous papillary, 
mucinous, endometrioid, clear cell, undifferentiated tumor and 
miscellaneous (leiomyosarcoma, mixed Müllerian sarcoma, 
Brenner tumor and granulosa tumor), respectively. Differentia-
tion was classified as well (grade 1), moderately (grade 2), and 
poorly differentiated (grade 3)  [28] . Data regarding size and loca-
tion of postoperative residual tumors, FIGO staging and histo-
logical grading were collected.
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 Statistical Analysis 
 The characteristics of the patients according to group are pre-
sented as means  8 SD. The unpaired Student t test was utilized 
for comparison of blood platelet count, serum hemoglobin, LDH, 
albumin and logarithmic-transformed CA 125 levels between the 
group with an optimal and suboptimal surgical debulking proce-
dure, respectively. The   2 test was performed for comparison of 
the presence of preoperative ascites between the previously men-
tioned groups. These results were exploited for the detection of 
initial predictive parameters between the group of patients with 
an optimal and that with a suboptimal surgical cytoreduction, 
respectively. Subsequently, univariate and multivariate analyses 
by logistic regression with regard to the presence of residual tu-
mor after the surgical intervention were performed. Backward 
stepwise elimination was utilized for the multivariate logistic 
analysis to predict patients remaining with residual tumor of 
 1 1 cm with p  ! 0.05 as cutoff level for elimination of non-signifi-
cant predictors from the prognostic model. The area under the 
receiver-operating characteristic (ROC) curve (AUC) was ex-
ploited to assess the discriminative ability of the logistic models. 
The AUC generates the proportion of pairs (each pair consisting 
of 1 patient without and the other patient with the presence of re-
sidual tumor after surgery) in which the model predicts a higher 
probability of postoperative residual tumor of  1 1 cm. A nomo-
gram was generated by combining the calculated predictive pa-
rameters in the entire population with the model predicting the 
postoperative result. In addition, the   2 test was utilized for com-
parison of the secondary outcome parameters, i.e. FIGO stage, 
histological classification and grading, respectively. p  ! 0.05 was 
considered to represent a statistically significant difference. The 
software package SPSS (SPSS, Chicago, Ill., USA) was employed 
for data analysis.
 As a result of the selection and estimation of eight potential 
predictors on a dataset with 85 events (patients with a suboptimal 
debulking procedure), correction for overfitting was performed 
 [29] . The internal validity of the prognostic model was tested by 
a bootstrapping method in which the selection and estimation 
process was repeated 200 times. Each of these repetitions con-
sisted of creating a new dataset (bootstrap sample) by drawing 
cases with replacement from the original data. The backward 
stepwise elimination process was performed on this dataset, 
yielding a set of selected predictors and parameter estimates  [29, 
30] . Resulting model estimates of each bootstrap sample were 
evaluated on the original data, and a shrinkage factor was esti-
mated to correct for statistical overoptimism. The Hosmer-Lem-
eshow goodness-of-fit test was used to check for lack of fit of the 
final model  [31] .
 Results 
 Recruitment and Demographic Characteristics
of the Patients 
 Of the 187 patients enrolled in the study, 8 patients 
were not eligible for the study due to a history of breast 
cancer (n = 2), ovarian carcinoma as chance finding (n = 
2), previous neoadjuvant chemotherapy (n = 2), or the di-
agnosis of a borderline tumor (n = 1) or colon carcinoma 
(n = 1;  fig. 1 ). In total, 179 patients with the clinical sus-
picion of advanced ovarian cancer undergoing a primary 
surgical cytoreduction procedure were analyzed. The 
median age of the patients was 61 (range 36–85) years and 
did not differ between the group with optimal cytore-
duction and the group with a residual tumor  1 1 cm. In 
94 patients (53%), an optimal cytoreduction has been 
achieved. Among the 179 patients who were initially clin-
ically staged as ovarian cancer at advanced stage, 36 pa-
tients were surgically staged as early-stage ovarian cancer 
(FIGO stage IA–IIA). Further details are listed in  ta-
ble 1 .
 Preoperative Parameters 
 The PS was comparable in both groups. However, the 
presence of ascites was increased in the suboptimally cy-
toreduced group (68 cases; 80%) compared to the opti-
mally cytoreduced group (47 cases; 50%; p  ! 0.0005,  ta-
ble 1 ). The mean serum concentration of logarithmically 
transformed CA 125 was higher in the group of patients 
with postoperative residual tumor compared to the opti-
mally cytoreduced group (2.88  8 0.68 vs. 2.51  8 0.71 
kU/l; p  ! 0.0001, respectively). Serum albumin concen-
trations were lower in the suboptimally cytoreduced 
group in comparison to the optimally cytoreduced group 
(30.5  8 8.1 vs. 36.6  8 5.8 g/l; p  ! 0.0001, respectively; 
 fig. 2 ). Serum hemoglobin was lower and blood platelets 
were higher in the group remaining with a residual tu-
mor  1 1 cm compared to the group with residual tumor 
 ! 1 cm (7.64  8 0.99 vs. 7.95  8 0.79 mmol/l, respectively, 
Study population
n = 187
Included in analysis
n = 179
Excluded from analysis
n = 8
Primary surgical debulking procedure
n = 179
Residual tumor <1 cm
n = 94
Residual tumor >1 cm
n = 85
 Fig. 1. Flow chart of the study population consisting of 187 pa-
tients with a suspected diagnosis of advanced-stage ovarian can-
cer (FIGO stage IIB–IV). Eight patients were excluded from
the analysis. Optimal cytoreduction, defined as residual tumor 
 ! 1 cm, was established in 53% of the patients. 
 de Jong et al.
 
Oncology 2007;72:293–301296
and 396  8 121 vs. 325  8 126 !  10 9 /l; p  ! 0.05 and  ! 0.01, 
respectively;  fig. 3 ). Serum LDH concentrations were 
comparable in both groups.
 Multivariate Analysis 
 The variables ascites, log CA 125, albumin, hemoglo-
bin and blood platelets were statistically significantly 
different between both groups. Multivariate logistic re-
gression, utilizing a backward elimination procedure, 
resulted in the subsequent elimination of blood plate-
lets, hemoglobin and ascites from the prediction model 
( table 2 ). As a consequence, the AUC of the ROC curve 
consisting of a combination of log CA 125 and albumin 
was 0.79 compared to the AUC of the ROC curve of 0.73 
of each of both parameters individually ( fig. 4 ). The 
shrinkage factor of 0.78 was estimated from the boot-
Table 1. Characteristics of the study population consisting of patients with suspected advanced-stage ovarian 
cancer
Characteristics Study group Residual tumor
61 cm
Residual tumor
<1 cm
p (2 test)
Patients 179 85 (47%) 94 (53%)
Age, years 62813 64812 61813 NS
Karnofsky PS, % 9587 9489 9685 NS
Ascites 115 (64%) 68 (80%) 47 (50%) <0.0005
Serum parameters
log CA 125, kU/l 2.7080.70 2.8880.68 2.5180.71 <0.0001
Albumin, g/l 33.587.1 30.588.1 36.685.8 <0.0001
Hemoglobin, mmol/l 7.8180.89 7.6480.99 7.9580.79 <0.05
Blood platelets, !109/l 3578123 3968121 3258126 <0.01
Means 8 SD or absolute numbers. Significant differences were assessed between the group with residual 
tumor 61 cm and the group with residual tumor <1 cm.
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 Fig. 2. Box and whisker plots of preoperative serum levels of CA 
125 ( a ) and albumin ( b ), in 94 optimally cytoreduced patients and 
85 patients with postoperative residual tumor  1 1 cm. Optimal 
surgical cytoreduction is defined as  ! 1 cm residual tumor  [26] . 
 * p  ! 0.0001. 
 Fig. 3. Box and whisker plots of preoperative serum levels of
hemoglobin ( a ) and blood platelets ( b ) in 94 optimally cytore-
duced patients and 85 patients with postoperative residual tumor 
 1 1 cm. Optimal surgical cytoreduction is defined as  ! 1 cm
residual tumor  [26] .  * p  ! 0.05;  * * p  ! 0.01. 
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strap procedure. This indicates that in case of replica-
tion of this analysis, the resulting coefficients of the fi-
nal model are on average 22% smaller. The Hosmer-
Lemeshow goodness of fit showed no lack of fit of the 
final model to the data (p  ! 0.05). The generated nomo-
gram, consisting of CA 125 and albumin, for the prob-
ability of remaining with residual tumor  1 1 cm is de-
picted in  figure 5 .
 FIGO Stage and Histology 
 In the group with residual tumor  1 1 cm, a higher 
FIGO stage was observed when compared to the opti-
mally cytoreduced group (  2 = 56.7, d.f. 6; p  ! 0.0001). 
The tumors of the patients in the suboptimally cytore-
duced group appeared to be less differentiated in com-
parison  to the optimally cytoreduced group (  2 = 7.4, d.f. 
2; p  ! 0.05). In addition, a different histogenetic classifi-
cation of the tumor between both groups was observed 
(  2 = 18.6, d.f. 6; p  ! 0.005).  Table 3  provides secondary 
outcome parameters.
Table 2. Backward stepwise elimination procedure of potential 
prognostic parameters
Variable Model log
likelihood
Model in
–2 log
likelihood
d.f. Significance 
of
difference
Step 1
Blood platelets –79.51 0.03 1 0.86
Hemoglobin –80.34 1.70 1 0.20
Ascites –80.64 2.30 1 0.13
Albumin –84.82 10.66 1 <0.01
log CA 125 –83.70 8.43 1 <0.01
Step 2
Hemoglobin –80.40 1.77 1 0.18
Ascites –80.72 2.43 1 0.12
Albumin –85.18 11.34 1 <0.01
log CA 125 –84.13 9.26 1 <0.01
Step 3
Ascites –81.66 2.54 1 0.11
Albumin –87.07 13.34 1 <0.01
log CA 125 –85.33 9.87 1 <0.01
Step 4
Albumin –90.31 17.29 1 <0.01
log CA 125 –88.93 14.53 1 <0.01
Logistic regression with backward elimination procedure of 
the potential predictive parameters blood platelets, hemoglobin, 
ascites, albumin, and CA 125. With step 4 the predictive pa-
rameters albumin and CA 125 for the prediction model are gen-
erated.
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 Fig. 4. ROC curves of preoperative CA 125 ( ––––; AUC = 0.73 ) and 
albumin (· · · · ·; AUC = 0.73) serum levels. – – – = The ROC curve 
of the prediction model consisting of both preoperative CA 125 
and albumin serum levels (AUC = 0.79).  
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 Fig. 5. Nomogram for the prediction of postoperative residual tu-
mor, defined as  1 1 cm  [26] . The left axis represents the preopera-
tive CA 125 serum level, the right axis represents the preoperative 
albumin serum level. A straight line drawn between the preop-
erative CA 125 and the serum albumin level indicates the proba-
bility of postoperative residual tumor for an individual patient 
with ovarian cancer. 
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 Discussion 
 The median age of 61 years at the time of diagnosis in 
the study population was consistent with previous studies 
reporting a median age ranging from 56 to 61 years; the 
distribution of histological characteristics and FIGO stage 
of ovarian carcinoma was also in agreement with previous 
studies  [8, 10, 32–35] . Based on preoperative criteria, all 
179 patients were clinically suspected for an advanced 
stage of ovarian cancer (FIGO stage IIB–IV). Postsurgical 
data differed in 36 patients who were surgically staged as 
early-stage ovarian cancer (FIGO stage IA–IIA).
 In addition to the considerable number of patients who 
were in early and not advanced stage of the disease, a small 
number of patients had non-epithelial ovarian cancer ac-
cording to postsurgical data. The concept of optimal de-
bulking in epithelial ovarian cancer is solely validated in 
the advanced stage. Histological data and surgical staging 
of ovarian cancer according to FIGO criteria  [27] were 
only assessed postoperatively. Including these (postsurgi-
cal) parameters aiming at establishing a preoperative pre-
diction model for optimal debulking in ovarian cancer 
may be considered as a contradictio in terminis. Conse-
quently, FIGO stage and histology, although important in 
the prognosis of ovarian cancer, were not considered as 
parameters in this analysis. A more accurate estimation 
of clinical staging, including histology, may be obtained 
by a preceding diagnostic laparoscopy  [36] . However, 
these data were not available for the population studied.
 PS and age in the group of patients with postoperative 
residual tumor and the group of optimally cytoreduced 
patients were comparable. After primary surgery, 53%
of our study patients, including those in the early stages 
of disease, were considered to be optimally cytoreduced 
( ! 1 cm residual tumor). Although consistent with other 
studies  [8, 32–35] , the optimal debulking rate achieved in 
this study may be low compared to other centers  [37] . Sur-
gical techniques utilized in the study population are con-
sidered as standard of care. However, ultra-aggressive cy-
toreduction including splenectomy and low anterior en 
bloc resection was subject to unfamiliarity  [38, 39] . This 
may at least partly explain the lower optimal cytoreduc-
tion rate observed. Alternatively, feasibility and supple-
mentary benefit of these aggressive techniques are un-
clear, and data of prospective randomized trials address-
ing these issues are lacking.
 In the group of optimally surgically cytoreduced pa-
tients, serum levels of CA 125 were lower compared to the 
suboptimally cytoreduced group. Indeed, previous studies 
demonstrated serum CA 125 levels may predict the cyto-
reducibility of ovarian cancer in patients with an advanced 
stage of the disease  [8, 32, 33, 35, 40] . They appeared to be 
elevated in case of tumor implants in the peritoneum  [41] . 
However, sensitivity and specificity of serum CA 125 lev-
els in the diagnosis of ovarian malignancies may be lim-
ited. In addition, the relationship between tumor load and 
serum levels of CA 125 is inconclusive  [42–44] .
 Serum albumin levels were significantly lower in the 
group of patients with postoperative residual tumor in 
comparison to optimally surgically cytoreduced patients. 
Table 3. Secondary outcome parameters (absolute numbers) of 
the study population consisting of patients with suspected ad-
vanced-stage ovarian cancer 
Parameters Study
group
Residual 
tumor
61 cm
Residual 
tumor
<1 cm
Signifi-
cance
FIGO stage 56.7, d.f. 6
p < 0.0001
IA–IIA 36 0 36
IIB 2 0 2
IIC 3 1 2
IIIA 7 1 6
IIIB 7 3 5
IIIC 93 55 37
IV 31 25 6
Total 179 85 94
Histologic grade 6.9, d.f. 2
p < 0.05
I 15 3 12
II 46 19 27
III 114 61 53
Total 175a 83b 92c
Histologic classification 18.6, d.f. 5
p < 0.01
Serous 112 62 50
Mucinous 15 6 9
Clear cell 14 2 12
Endometrioid 10 0 10
Undifferentiated 22 12 10
Miscellaneous 6 3 3
Total 179 85 94
Significant differences between the group with residual tumor 
61 cm and the group with residual tumor <1 cm were assessed 
by 2 tests with d.f. representing the degrees of freedom.
a In 4 patients histologic grading was not performed.
b Two patients with a granulosa tumor.
c One patient with a mixed Müllerian tumor and 1 patient with 
a leiomyosarcoma.
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Albumin might be predictive for survival in patients with 
an advanced stage of ovarian carcinoma  [23, 45] . In addi-
tion, a preoperative serum albumin level  ! 35 g/l may in-
dicate a poor prognosis in terms of survival  [23] . Conse-
quently, serum levels of albumin may be a predictor for 
cytoreducibility of ovarian cancer. A possible explanation 
for this feature is that in case of disseminated disease, in-
tra-abdominal tumor cells may preclude the resorption of 
peritoneal fluid, resulting in hypoalbuminemia  [46] . In 
this study, the preoperative presence of ascites may indi-
cate the cytoreducibility of patients with ovarian cancer 
in case the backward stepwise elimination in the multi-
variate logistic analysis was lacking serum albumin. In-
deed, the presence of ascites is in turn related to serum 
albumin levels  [23] . Previous studies demonstrated that 
the presence of ascites is related to the survival of patients 
with an advanced stage of ovarian cancer  [10, 23] .
 This study showed decreased preoperative hemoglo-
bin levels in the group of patients with postoperative re-
sidual tumor in comparison to the optimally cytoreduced 
group. In addition, blood platelet count was elevated in 
the group with residual tumor. Although various studies 
demonstrated that low hemoglobin serum levels are re-
lated to poor survival in patients with ovarian cancer, a 
causal relationship remains to be established  [11, 22, 47] . 
However, a relatively low serum level of hemoglobin may 
contribute to induction of angiogenesis and proliferation 
of tumor cells, reflecting an advanced stage of disease 
 [48] . In addition, thrombocytosis might be an indepen-
dent prognostic factor for the progression of disease and 
outcome of second-look laparotomy  [9] . Serum LDH lev-
els were comparable in the patients with suboptimal and 
optimal cytoreduction. Although LDH may have a pre-
dictive value for the prognosis of ovarian carcinoma, the 
relationship between LDH and the result of the surgical 
intervention was absent in this study  [10, 49] .
 In accordance with previous studies, a multivariate 
analysis was employed to identify parameters predicting 
cytoreducibility of ovarian carcinoma  [8, 10, 47] . Of all po-
tential parameters, solely the preoperative serum levels of 
CA 125 and albumin were able to predict the chance of an 
optimal surgical cytoreduction (when analyzed by multi-
variate logistic regression with backward elimination pro-
cedure). The AUC of the ROC curve for these parameters 
combined was approximately 80%. These two parameters 
were the independently predictive factors in the analysis, 
and the eliminated parameters may be mutually related. 
As suggested before, serum albumin and the presence of 
ascites are related in ovarian cancer. However, albumin is 
the stronger predictor when analyzed in these terms.
 In addition to the multivariate analysis, a nomogram 
based on these two parameters was generated according to 
a previously published method  [50] . With the nomogram, 
the risk of postoperative residual tumor can be estimated 
for each individual patient. When optimal cytoreduction 
may be at stake, alternative treatments may be considered 
 [51] . These data should be interpreted with caution. Al-
though the proposed nomogram was internally validated, 
an external validation remains mandatory to apply the no-
mogram routinely in a wider context. In addition, bias re-
lated to inclusion and exclusion criteria could not be ruled 
out. A total of 3 patients, receiving a regimen of neoadju-
vant chemotherapy, were not included in the trial. The no-
mogram is designed to select particularly patients eligible 
for an alternative approach. However, the ongoing EORTC 
55971 trial, comparing neoadjuvant chemotherapy to up-
front surgical cytoreduction in patients with an advanced 
stage of ovarian carcinoma, may establish the viability of 
such an alternative approach  [52] .
 Upfront debulking in advanced epithelial ovarian 
cancer remains the standard of care until non-inferiority 
trials demonstrate that a regimen of neoadjuvant chemo-
therapy may lead to similar results in terms of survival. 
Survival rates in patients with postoperative residual tu-
mor  ! 1 cm are higher compared to those with  1 1 cm re-
sidual tumor  [26, 28] . However, radical surgery is associ-
ated with higher morbidity rates that may subsequently 
result in lower survival rates  [53] . Hence, a regimen of 
neoadjuvant chemotherapy might be considered in ASA 
1 and 2 patients with an approximately 80% predicted 
chance of residual tumor while neoadjuvant chemother-
apy may be an acceptable alternative in ASA 3 and 4 pa-
tients with a much lower chance of residual tumor  [54] .
 In conclusion, differences in preoperative serum levels 
of CA 125, albumin, hemoglobin and blood platelets were 
established between patients with postoperative residual 
tumor and those with an optimal surgical cytoreduction, 
as was the presence of ascites. In addition, serum CA 125 
levels combined with serum albumin were strong preop-
erative predictors for tumor resectability in patients with 
ovarian cancer. In each individual patient with a suspect-
ed diagnosis of advanced-stage ovarian cancer, the pro-
posed nomogram could be applied to inform the patient 
and to select the most effective treatment modality.
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